Melissa Deck

Director of Platform at Liberate Bio

Speaker

Melissa Deck is a strategic scientific leader with deep expertise in molecular biology and nonclinical development across the pharma, biotech, and startup sectors. She has led high-impact programs involving CRISPR/Cas9 genome editing, LNP screening, and AAV gene therapy. With a strong background in in vivo pharmacology, assay development, and editing platforms, Melissa has directed cross-functional teams and external collaborations to advance novel therapeutics. Currently Director of Platform at Liberate Bio, she previously held leadership roles at Carver Biosciences, Arbor Biotherapeutics, and Gemini Therapeutics, consistently driving innovation in nucleic acid-based drug development and delivery.